322 related articles for article (PubMed ID: 24776733)
1. Hyperinsulinaemic androgen excess in adolescent girls.
Ibáñez L; Ong KK; López-Bermejo A; Dunger DB; de Zegher F
Nat Rev Endocrinol; 2014 Aug; 10(8):499-508. PubMed ID: 24776733
[TBL] [Abstract][Full Text] [Related]
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
Ibáñez L; Potau N; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2000 Sep; 85(9):3251-5. PubMed ID: 10999817
[TBL] [Abstract][Full Text] [Related]
4. Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Díaz M; Gallego-Escuredo JM; de Zegher F; Villarroya F; Ibáñez L
Diabetes Metab; 2016 Jun; 42(3):196-9. PubMed ID: 26546387
[No Abstract] [Full Text] [Related]
5. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Ibáñez L; Diaz M; Sebastiani G; Sánchez-Infantes D; Salvador C; Lopez-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2011 Nov; 96(11):3361-6. PubMed ID: 21865363
[TBL] [Abstract][Full Text] [Related]
6. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
7. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity.
Ibáñez L; Díaz M; Sebastiani G; Marcos MV; López-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2013 May; 98(5):E902-7. PubMed ID: 23547047
[TBL] [Abstract][Full Text] [Related]
8. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Ibáñez L; Valls C; Potau N; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2000 Oct; 85(10):3526-30. PubMed ID: 11061495
[TBL] [Abstract][Full Text] [Related]
9. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Ibáñez L; López-Bermejo A; del Rio L; Enríquez G; Valls C; de Zegher F
J Clin Endocrinol Metab; 2007 May; 92(5):1710-4. PubMed ID: 17299064
[TBL] [Abstract][Full Text] [Related]
10. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; del Río L; de Zegher F
Clin Endocrinol (Oxf); 2009 Sep; 71(3):351-7. PubMed ID: 19018783
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; Valls C; de Zegher F
Clin Endocrinol (Oxf); 2008 Feb; 68(2):317-20. PubMed ID: 18031315
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Ibáñez L; Valls C; Ferrer A; Ong K; Dunger DB; De Zegher F
J Clin Endocrinol Metab; 2002 Jun; 87(6):2870-4. PubMed ID: 12050266
[TBL] [Abstract][Full Text] [Related]
13. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Ibáñez L; López-Bermejo A; Díaz M; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1262-7. PubMed ID: 21632811
[TBL] [Abstract][Full Text] [Related]
14. Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Díaz M; Chacón MR; López-Bermejo A; Maymó-Masip E; Salvador C; Vendrell J; de Zegher F; Ibáñez L
J Clin Endocrinol Metab; 2012 Oct; 97(10):3630-8. PubMed ID: 22791755
[TBL] [Abstract][Full Text] [Related]
15. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception.
Ibáñez L; Jaramillo AM; Ferrer A; de Zegher F
Hum Reprod; 2005 Sep; 20(9):2457-62. PubMed ID: 15905296
[TBL] [Abstract][Full Text] [Related]
16. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Ibáñez L; Ong K; Ferrer A; Amin R; Dunger D; de Zegher F
J Clin Endocrinol Metab; 2003 Jun; 88(6):2600-6. PubMed ID: 12788862
[TBL] [Abstract][Full Text] [Related]
17. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study.
West S; Lashen H; Bloigu A; Franks S; Puukka K; Ruokonen A; Järvelin MR; Tapanainen JS; Morin-Papunen L
Hum Reprod; 2014 Oct; 29(10):2339-51. PubMed ID: 25085801
[TBL] [Abstract][Full Text] [Related]
18. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Romualdi D; Guido M; Ciampelli M; Giuliani M; Leoni F; Perri C; Lanzone A
Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448
[TBL] [Abstract][Full Text] [Related]
19. Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype.
Ong KK; de Zegher F; López-Bermejo A; Dunger DB; Ibáñez L
Eur J Endocrinol; 2007 Nov; 157(5):661-8. PubMed ID: 17984247
[TBL] [Abstract][Full Text] [Related]
20. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study.
Pinola P; Lashen H; Bloigu A; Puukka K; Ulmanen M; Ruokonen A; Martikainen H; Pouta A; Franks S; Hartikainen AL; Järvelin MR; Morin-Papunen L
Hum Reprod; 2012 Nov; 27(11):3279-86. PubMed ID: 22933528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
